03/13/2026
NEW TREATMENT FOR PREECLAMPSIA BEING TESTED TO IMPROVE OUTCOMES FOR PREGNANT WOMEN!!
A cross-disciplinary team, including Jennifer McIntosh, DO as the PI, has launched a clinical trial to test a promising treatment that could improve outcomes for both pregnant patients and their babies.
The trial, supported by a grant from the Gates Foundation through Grand Challenges, is testing whether the supplement MitoQ can improve vascular function in patients with preeclampsia, ultimately leading to longer, healthier pregnancies.
“There is currently no medication that can cure preeclampsia or really even hold it at bay,” says Jennifer McIntosh, MS, DO, associate professor of obstetrics and gynecology and a maternal fetal medicine specialist who is leading the research. “The mother can become very sick, and currently the only definitive treatment is to deliver the baby, which can mean that the newborn ends up in intensive care. We are excited by what we’ve seen in our research so far, and we hope this shows that it can help with vascular dysfunction.”
The two-year, $900,000 award was funded by the Gates Foundation through Grand Challenges, a global partnership that catalyzes innovation and serves as a platform for partners to collaborate and drive lasting impact.
Preeclampsia – persistent high blood pressure during pregnancy – affects up to 8 percent of pregnant women worldwide. Though many women with preeclampsia give birth to healthy babies, the condition…